RNAZ White background cropped.jpg
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
29 nov. 2024 16h25 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
RNAZ White background cropped.jpg
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
27 nov. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
RNAZ White background cropped.jpg
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
25 nov. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
RNAZ White background cropped.jpg
TransCode Therapeutics Open Letter to Shareholders
12 nov. 2024 07h00 HE | TransCode Therapeutics, Inc.
Open Letter to Shareholders
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
05 nov. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
23 oct. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
RNAZ White background cropped.jpg
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
10 oct. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
RNAZ White background cropped.jpg
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17 sept. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
PrismHR-Logos_HEX__Color.png
Marrying Form and Function, PrismHR Unveils New Unified Employee Experience (UEX)
12 oct. 2023 15h13 HE | PrismHR
PrismHR Unveils New Unified Employee Experience (UEX)
Kevin-Andrews-PrismHR-300
Kevin Andrews Named President of PrismHR
05 oct. 2023 07h00 HE | PrismHR
Kevin Andrews Named President of PrismHR